Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ben Lin Hom"'
Autor:
Ben Lin Hom, Sarah A. Taylor, Robert B. Livingston, Ronald B. Natale, James K. Weick, John Crowley, Saul E. Rivkin, Charles A. Coltman
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 9(7)
Six hundred eighty assessable patients with measureable stage III M1, non-small-cell lung cancer (NSCLC) were randomized to one of five treatment arms including cisplatin, etoposide (VP-16) +/- methylglyoxal bisguanylhydrazone (MGBG; PVp, PVpM); cisp
Autor:
Ben Lin Hom, Robert Chapman, Joel G. Lucas, Harry E. Hynes, John Crowley, Clarence B. Vaughn, Robert B. Livingston
Publikováno v:
Investigational New Drugs. 11:91-92
This trial employing MGBG, vinblastine, and cisplatin in patients with advanced NSCLC produced a 10% response rate with no durable responses. This is disappointing compared to previously cited studies, although the median overall survival of 7.0 mont
Autor:
Ben Lin Hom
Publikováno v:
Acta Haematologica. 75:178-180
Bone marrow examination in a 78-year-old woman showed a plasmacytosis with prominent erythrophagocytosis, secretory activity and numerous Russell bodies. Subsequent evaluation disclosed a monoclonal protein of IgA-kappa type and clinical and laborato
Autor:
Ben Lin Hom
Publikováno v:
American Journal of Clinical Pathology. 82:627-629
A 55-year-old man presented with nerve compression and examination of tissue removed by laminectomy, and bone marrow aspiration was diagnostic of multiple myeloma. Protein studies showed a total serum protein of 5.7 g/dL, with a M-component in the fa
Publikováno v:
Human Pathology. 16:1175-1177
The case of a patient in whom idiopathic thrombocytopenic purpura (ITP) was associated with diffuse splenic histiocytosis is described; the patient's subsequent sphingomyelinase level was at the lower limits of the normal range. The patient's splenic
Autor:
Ben Lin Hom
Publikováno v:
JAMA: The Journal of the American Medical Association. 252:2007-2007
To the Editor.— The letter by Schacter et al1appears to be based on lung cancer statistics from a cancer registry and patients seen at a medical center. These are at variance with State of Hawaii Tumor Registry statistics and the experience of the